Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 4/20 | 0.45 |
| ▸ | FOLH1 | Q04609 | 4/20 | 0.43 |
| ▸ | GLP1R | P43220 | 8/20 | 0.43 |
| ▸ | FNTA | P49354 | 2/20 | 0.42 |
| ▸ | FNTB | P49356 | 2/20 | 0.42 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.41 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.41 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.41 |
| ▸ | RARB | P10826 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15530711 | 1.00 | NOD1 (0.45) | NOD1FOLH1GLP1RFNTAFNTB | |
| SCHEMBL4538768 | 1.00 | NOD1 (0.45) | NOD1FOLH1GLP1RFNTAFNTB | |
| SCHEMBL15530471 | 1.00 | NOD1 (0.45) | NOD1FOLH1GLP1RFNTAFNTB | |
| SCHEMBL16699991 | 1.00 | NOD1 (0.45) | NOD1FOLH1GLP1RFNTAFNTB | |
| SCHEMBL16699153 | 1.00 | NOD1 (0.45) | NOD1FOLH1GLP1RFNTAFNTB | |
| SCHEMBL4542736 | 1.00 | NOD1 (0.45) | NOD1FOLH1GLP1RFNTAFNTB | |
| SCHEMBL15530791 | 0.95 | FOLH1 (0.47) | NOD1FOLH1GLP1RITGB3ITGA2B | |
| SCHEMBL4529990 | 0.95 | FOLH1 (0.47) | NOD1FOLH1GLP1RITGB3ITGA2B | |
| SCHEMBL4533630 | 0.95 | FOLH1 (0.47) | NOD1FOLH1GLP1RITGB3ITGA2B | |
| SCHEMBL15529970 | 0.95 | FOLH1 (0.47) | NOD1FOLH1GLP1RITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2637699-B1 | DOUBLE-ACYLATED GLP-1 DERIVATIVES WITH A LINKER | NOVO NORDISK AS (DK) | 2018-05-16 | — | — | EP | claimed |
| EP-2846824-B1 | DOUBLE-ACYLATED GLP-1 DERIVATIVES | NOVO NORDISK AS (DK) | 2017-04-05 | — | — | EP | claimed |
| US-11518795-B2 | Double-acylated GLP-1 derivatives | NOVO NORDISK A/S (DK) | 2022-12-06 | — | — | US | disclosed |
| US-20200123215-A1 | Double-Acylated GLP-1 Derivatives | NOVO NORDISK AS (DK) | 2020-04-23 | — | — | US | disclosed |
| US-10604554-B2 | Double-acylated GLP-1 derivatives | NOVO NORDISK A/S (DK) | 2020-03-31 | — | — | US | disclosed |
| US-20180244742-A1 | Double-Acylated GLP-1 Derivatives | NOVO NORDISK AS (DK) | 2018-08-30 | — | — | US | disclosed |
| US-10000542-B2 | Double-acylated GLP-1 derivatives | NOVO NORDISK A/S (DK) | 2018-06-19 | — | — | US | disclosed |
| EP-2637699-B1 | DOUBLE-ACYLATED GLP-1 DERIVATIVES WITH A LINKER | NOVO NORDISK AS (DK) | 2018-05-16 | — | — | EP | disclosed |
| EP-2846824-B1 | DOUBLE-ACYLATED GLP-1 DERIVATIVES | NOVO NORDISK AS (DK) | 2017-04-05 | — | — | EP | disclosed |
| US-20150210745-A1 | Double-Acylated GLP-1 Derivatives with a Linker | NOVO NORDISK AS (DK) | 2015-07-30 | — | — | US | disclosed |
| US-20150152157-A1 | Double-Acylated GLP-1 Derivatives | NOVO NORDISK A/S (DK) | 2015-06-04 | — | — | US | disclosed |
| US-20150133374-A1 | Double-Acylated GLP-1 Derivatives | NOVO NORDISK A/S (DK) | 2015-05-14 | — | — | US | disclosed |
| US-9006178-B2 | Double-acylated GLP-1 derivatives with a linker | NOVO NORDISK A/S (DK) | 2015-04-14 | — | — | US | disclosed |
| EP-2846823-A1 | DOUBLE-ACYLATED GLP-1 DERIVATIVES | Novo Nordisk A/S (DK) | 2015-03-18 | — | — | EP | disclosed |
| EP-2846824-A1 | DOUBLE-ACYLATED GLP-1 DERIVATIVES | Novo Nordisk A/S (DK) | 2015-03-18 | — | — | EP | disclosed |
| US-20130338068-A1 | DOUBLE-ACYLATED GLP-1 DERIVATIVES WITH A LINKER | NOVO NORDISK A/S (DK) | 2013-12-19 | — | — | US | disclosed |
| WO-2013167454-A1 | DOUBLE-ACYLATED GLP-1 DERIVATIVES | NOVO NORDISK A/S (DK) | 2013-11-14 | — | — | WO | disclosed |
| WO-2013167455-A1 | DOUBLE-ACYLATED GLP-1 DERIVATIVES | NOVO NORDISK A/S (DK) | 2013-11-14 | — | — | WO | disclosed |
| EP-2637699-A1 | DOUBLE-ACYLATED GLP-1 DERIVATIVES WITH A LINKER | Novo Nordisk A/S (DK) | 2013-09-18 | — | — | EP | disclosed |
| WO-2012062804-A1 | DOUBLE-ACYLATED GLP-1 DERIVATIVES WITH A LINKER | NOVO NORDISK A/S (DK) | 2012-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150210745-A1 | Double-Acylated GLP-1 Derivatives with a Linker | GLP1R, VIP, IAPP | NOD1 417/4885FOLH1 1941/4885GLP1R 1/4885 |
| US-20150152157-A1 | Double-Acylated GLP-1 Derivatives | GLP1R, GIPR, GPR119 | NOD1 1259/4885FOLH1 1142/4885GLP1R 1/4885 |
| US-20150133374-A1 | Double-Acylated GLP-1 Derivatives | GLP1R, GIPR, GPR119 | NOD1 1050/4885FOLH1 1143/4885GLP1R 1/4885 |
| US-10604554-B2 | Double-acylated GLP-1 derivatives | GLP1R, GIPR, GPR119 | NOD1 1050/4885FOLH1 1143/4885GLP1R 1/4885 |
| US-20180244742-A1 | Double-Acylated GLP-1 Derivatives | GLP1R, GIPR, GPR119 | NOD1 1021/4885FOLH1 1126/4885GLP1R 1/4885 |
| US-10000542-B2 | Double-acylated GLP-1 derivatives | GLP1R, GIPR, GPR119 | NOD1 1050/4885FOLH1 1143/4885GLP1R 1/4885 |
| US-20130338068-A1 | DOUBLE-ACYLATED GLP-1 DERIVATIVES WITH A LINKER | GLP1R, VIP, IAPP | NOD1 468/4885FOLH1 1753/4885GLP1R 1/4885 |
| US-20200123215-A1 | Double-Acylated GLP-1 Derivatives | GLP1R, GIPR, GPR119 | NOD1 1050/4885FOLH1 1143/4885GLP1R 1/4885 |
| US-11518795-B2 | Double-acylated GLP-1 derivatives | GLP1R, GIPR, GPR119 | NOD1 1050/4885FOLH1 1143/4885GLP1R 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.